No Yes Ok

Archive

« Older Entries

LSP's portfolio company Arvelle announces FDA approval of anti-epileptic drug cenobamate Friday, December 13th, 2019
Amsterdam, 26 November 2019 - LSP's portfolio company Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, announced [...]
LSP 5 portfolio company ImCheck Therapeutics raises € 48 million ($ 53 million) to drive clinical program for cancer and autoimmune diseases Friday, December 6th, 2019
Amsterdam, The Netherlands, December 04, 2019 – LSP, the leading European life sciences investor, today announced the closing of a €48 million ($53 million) Series B financing of ImCheck Therapeutics, a biotech co [...]
SCOPE 'Dossier Private equity' Thursday, November 7th, 2019
In de bijzondere seminareditie van Mgmt. SCOPE 'Dossier Private equity' een uitgebreid interview met 4 millennials (waaronder LSP's Felice Verduyn) waarin zij hun uitgebreide visie geven op de toekomst van [...]
LSP portfolio company ARGENX successfully raises $484 million in a public offering Thursday, November 7th, 2019
LSP portfolio company ARGENX successfully raises $484 million in a public offering, for more info please read attached press release: https://www.argenx.com/en-GB/news-internal/argenx-raises-484-million-in-gross-proce [...]
LSP portfolio company Merus successfully raises $68.9 million in a public offering Thursday, November 7th, 2019
LSP portfolio company Merus successfully raises $68.9 million in a public offering, for more info please read attached press release: https://ir.merus.nl/news-releases/news-release-details/merus-announces-pricing-pub [...]
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions Sunday, October 27th, 2019
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer [...]
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury Tuesday, October 22nd, 2019
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX medical BV (‘GTX’, formerly known as G-Therapeutics) and NeuroRecovery Technologies Inc. (‘NRT’) today announced their merger to crea [...]
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury Tuesday, October 22nd, 2019
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX medical BV (‘GTX’, formerly known as G-Therapeutics) and NeuroRecovery Technologies Inc. (‘NRT’) today announced their merger to crea [...]
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist Wednesday, September 18th, 2019
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammat [...]
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round Wednesday, September 11th, 2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri [...]

« Older Entries

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries

LSP's portfolio company Arvelle announces FDA approval of anti-epileptic drug cenobamate Friday, December 13th, 2019
Amsterdam, 26 November 2019 - LSP's portfolio company Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, announced [...]
LSP 5 portfolio company ImCheck Therapeutics raises € 48 million ($ 53 million) to drive clinical program for cancer and autoimmune diseases Friday, December 6th, 2019
Amsterdam, The Netherlands, December 04, 2019 – LSP, the leading European life sciences investor, today announced the closing of a €48 million ($53 million) Series B financing of ImCheck Therapeutics, a biotech co [...]
SCOPE 'Dossier Private equity' Thursday, November 7th, 2019
In de bijzondere seminareditie van Mgmt. SCOPE 'Dossier Private equity' een uitgebreid interview met 4 millennials (waaronder LSP's Felice Verduyn) waarin zij hun uitgebreide visie geven op de toekomst van [...]
LSP portfolio company ARGENX successfully raises $484 million in a public offering Thursday, November 7th, 2019
LSP portfolio company ARGENX successfully raises $484 million in a public offering, for more info please read attached press release: https://www.argenx.com/en-GB/news-internal/argenx-raises-484-million-in-gross-proce [...]
LSP portfolio company Merus successfully raises $68.9 million in a public offering Thursday, November 7th, 2019
LSP portfolio company Merus successfully raises $68.9 million in a public offering, for more info please read attached press release: https://ir.merus.nl/news-releases/news-release-details/merus-announces-pricing-pub [...]
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions Sunday, October 27th, 2019
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer [...]
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury Tuesday, October 22nd, 2019
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX medical BV (‘GTX’, formerly known as G-Therapeutics) and NeuroRecovery Technologies Inc. (‘NRT’) today announced their merger to crea [...]
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury Tuesday, October 22nd, 2019
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX medical BV (‘GTX’, formerly known as G-Therapeutics) and NeuroRecovery Technologies Inc. (‘NRT’) today announced their merger to crea [...]
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist Wednesday, September 18th, 2019
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammat [...]
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round Wednesday, September 11th, 2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri [...]

« Older Entries

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund